Preventive Health Care, 2001 Update: Colorectal Cancer Screening

Prepared  by R. McLeod, MD, FRCSC, FACS, with the Canadian Task Force on Preventive Health Care

These recommendations were finalized by the Task Force in January 2000.

  1. National Cancer Institute of Canada. Canadian Cancer Statistics 2000.  2000. Toronto, Canada.

  2. Wilson SM, Beahrs OH.  The curative treatment of carcinoma of the sigmoid, rectosigmoid, and rectum. Ann Surg 1976; 183(5):556-565.

  3. Toribara NW, Sleisenger MH. Screening for colorectal cancer. N Engl J Med 1995; 332(13):861-867.

  4. Solomon MJ, McLeod RS. Periodic health examination, 1994 update: 2. Screening strategies for colorectal cancer. Canadian Task Force on the Periodic Health Examination. CMAJ 1994; 150(12):1961-1970.

  5. Simon JB. Fecal occult blood testing: clinical value and limitations. Gastroenterologist 1998; 6(1):66-78.

  6. Ahlquist DA, McGill DB, Schwartz S, Taylor WF, Owen RA. Fecal blood levels in health and disease. A study using HemoQuant. N Engl J Med 1985; 312(22):1422-1428.

  7. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334(3):155-159.

  8. Robinson MH, Marks CG, Farrands PA, Thomas WM, Hardcastle JD. Population screening for colorectal cancer: comparison between guaiac and immunological faecal occult blood tests. Br J Surg 1994; 81(3):448-451.

  9. US Preventive Services Task Force. Screening for colorectal cancer. Guide to Clinical Preventive Services. Alexandria, Virginia: International Medical Publishing Inc. 1996: 89-103.

  10. Cummings BJ. A critical review of adjuvant preoperative radiation therapy for adenocarcinoma of the rectum. Br J Surg 1986; 73(5):332-338.

  11. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319(9 ):525-532.

  12. Stephenson BM, Finan PJ, Gascoyne J, Garbett F, Murday VA, Bishop DT. Frequency of familial colorectal cancer. Br J Surg 1991; 78(10):1162-1166.

  13. Australian Health Technology Advisory Committee. Colorectal Cancer Screening. A Report of the Australian Health Technology Advisory Committee.  1997.

  14. Lennard-Jones JE, Melville DM, Morson BC, Ritchie JK,  Williams CB. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. Gut 1990; 31(7):800-806.

  15. Wolff SH, Battista RN, Anderson GM, Logan AG, Wang E. Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. A report by the Canadian Task Force on the Periodic Health Examination. J Clin Epidemiol 1990; 43(9):891-905.

  16. Gilbertsen VA, Church TR, Grewe FJ, Mandel JS, McHugh RB, Schuman LM et al. The design of a study to assess occult-blood screening for colon cancer. J Chronic Dis 1980; 33( 2):107-114.

  17. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328(19):1365-1371.

  18. Mandel JS, Bond JH, Snover DC et al. The University of Minnesota's Colon Cancer Control Study: Design and progress to date. In: Chamberlain J, Miller AB, editors. Screening for Gastrointestinal Cancer. Toronto: Huber, 1998: 434-437.

  19. Mandel JS, Bond JH, Bradley M, Snover DC, Church TR, Williams S et al. Sensitivity, specificity, and positive predictivity of the Hemoccult test in screening for colorectal cancers. The University of Minnesota's Colon Cancer Control Study. Gastroenterology 1989;  97(3):597-600.

  20. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999; 91(5):434-437.

  21. Kronborg O, Fenger C,  Olsen J, Bech K, Sondergaard O. Repeated screening for colorectal cancer with fecal occult blood test. A prospective randomized study at Funen, Denmark. Scand J Gastroenterol 1989; 24(5):599-606.

  22. Jensen BM, Kronborg O, Fenger C. Interval cancers in screening with fecal occult blood test for colorectal cancer. Scand J Gastroenterol 1992; 27(9):779-782.

  23. Kronborg O, Fenger C,  Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348(9040):1467-1471.

  24. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348(9040):1472-1477.

  25. Hardcastle JD, Thomas WM, Chamberlain J, Pye G, Sheffield J, James PD et al. Randomised, controlled trial of faecal occult blood screening for colorectal cancer. Results for first 107,349 subjects. Lancet 1989; 1(8648):1160-1164.

  26. Kewenter J, Brevinge H, Engaras B, Haglind E, Ahren C. Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. Results for 68,308 subjects. Scand J Gastroenterol 1994; 29(5):468-473.

  27. Kewenter J, Bjork S, Haglind E, Smith L, Svanvik J, Ahren C. Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects. Cancer 1988; 62(3):645-651.

  28. Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ 1998; 317(7158):559-565.

  29. Winawer SJ, Andrews M, Flehinger B, Sherlock P, Schottenfeld D, Miller DG. Progress report on controlled trial of fecal occult blood testing for the detection of colorectal neoplasia. Cancer 1980; 45(12):2959-2964.

  30. Winawer SJ, Fleisher M, Baldwin M, Sherlock P. Current status of fecal occult blood testing in screening for colorectal cancer. CA Cancer J Clin 1982; 32(2):100-112.

  31. Winawer SJ, Schottenfeld D, Flehinger BJ. Colorectal cancer screening. J Natl Cancer Inst 1991; 83(4):243-253.

  32. Faivre J, Arveux P, Milan C, Durand G, Lamour J, Bedenne L. Participation in mass screening for colorectal cancer: results of screening and rescreening from the Burgundy study [see comments]. Eur J Cancer Prev 1991; 1(1):49-55.

  33. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schulman LM : The effect of fecal occult blood screening on the incidence of colorectal cancer.  N Engl J Med  2000;343:1603-7.

  34. Lang CA, Ransohoff DF. Fecal occult blood screening for colorectal cancer. Is mortality reduced by chance selection for screening colonoscopy? JAMA 1994; 271(13):1011-1013.

  35. Vernon SW. Participation in colorectal cancer screening: a review. J Natl Cancer Inst 1997; 89(19):1406-1422.

  36. Blalock SJ, DeVellis BM, Sandler RS. Participation in fecal occult blood screening: a critical review. Prev Med 1987; 16(1):9-18.

  37. Friedman GD, Collen MF, Fireman BH. Multiphasic Health Checkup Evaluation: a 16-year follow-up. J Chronic Dis 1986; 39(6):453-463.

  38. Selby JV, Friedman GD, Quesenberry CP, Jr., Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992; 326(10):653-657.

  39. Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality [see comments]. J Natl Cancer Inst 1992; 84(20):1572-1575.

  40. Muller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans [see comments]. Arch Intern Med 1995; 155(16):1741-1748.

  41. Gilbertsen VA. Proctosigmoidoscopy and polypectomy in reducing the incidence of rectal cancer. Cancer 1974; 34(3):suppl-9.

  42. Gilbertsen VA, Nelms JM. The prevention of invasive cancer of the rectum. Cancer 1978; 41(3):1137-1139.Hertz R, Deddish M, Day E. Value of periodic examinations in detecting cancer of the colon and rectum. Postgrad Med 1960; 27:290-294.

  43. Hertz R, Deddish M, Day E.  Value of periodic examinations in detecting cancer of the colon and rectum.  Postgrad Med  1960;27:290-294.

  44. Verne JE, Aubrey R, Love SB, Talbot IC, Northover JM. Population based randomized study of uptake and yield of screening by flexible sigmoidoscopy compared with screening by faecal occult blood testing. BMJ 1998; 317(7152):182-185.

  45. Berry DP, Clarke P, Hardcastle JD, Vellacott KD. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening. Br J Surg 1997; 84(9):1274-1276.

  46. Rasmussen M, Kronberg O, Fenger C, Jorgensen OD.  Possible advantages and drawbacks of adding flexible sigmoidoscopy to Hemoccult – II in screening for colorectal cancer.  A randomized study.  1999;34:73-78.

  47. Grobe JL, Kozarek RA,  Sanowski RA. Flexible versus rigid sigmoidoscopy: a comparison using an inexpensive 35-cm flexible proctosigmoidoscope. Am J Gastroenterol 1983; 78(9):569-571.

  48. Winawer SJ, Miller C, Lightdale C, Herbert E, Ephram RC, Gordon L et al. Patient response to sigmoidoscopy. A randomized, controlled trial of rigid and flexible sigmoidoscopy. Cancer 1987; 60(8):1905-1908.

  49. Winnan G, Berci G, Panish J, Talbot TM, Overholt BF, McCallum RW. Superiority of the flexible to the rigid sigmoidoscope in routine proctosigmoidoscopy. N Engl J Med 1980; 302(18):1011-1012.

  50. Read TE, Read JD, Butterly LF. Importance of adenomas 5 mm or less in diameter that are detected by sigmoidoscopy [see comments]. N Engl J Med 1997; 336(1 ):8-12.

  51. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas [see comments]. N Engl J Med 1992; 326(10):658-662.

  52. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransahoff DF : Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings.  N Engl J Med  2000;343:169-174.

  53. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G for the Veteran Affairs Study Group 380.  N Engl J Med  2000;343:162-168.

  54. Atkin WS. Flexible sigmoidoscopy as a mass screening tool. Eur J Gastroenterol Hepatol 1998; 10(3):219-223.

  55. Atkin WS, Hart A, Edwards R, McIntyre P, Aubrey R, Wardle J et al. Uptake, yield of neoplasia, and adverse effects of flexible sigmoidoscopy screening. Gut 1998; 42(4):560-565.

  56. Kramer BS, Gohagan J,  Prorok PC, Smart C. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 1993; 71(2 Suppl):589-593.

  57. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup [see comments]. N Engl J Med 1993; 329(27):1977-1981.

  58. Ballantyne GH, Savoca PE, Flemming FX et al.  Screening colonoscopy in asymptomatic patients. Dis Colon Rectum 1990; 3(Suppl):14.

  59. Johnson DA, Gurney MS, Volpe RJ, Jones DM, VanNess MM, Chobanian SJ et al. A prospective study of the prevalence of colonic neoplasms in asymptomatic patients with an age-related risk. Am J Gastroenterol 1990; 85(8):969-974.

  60. Rex DK, Sledge GW, Harper PA, Ulbright TM, Loehrer PJ, Helper DJ et al. Colonic adenomas in asymptomatic women with a history of breast cancer. Am J Gastroenterol 1993; 88(12):2009-2014.

  61. Vasen HF, Griffioen G, Tops CM, van Haeringen A, Nagengast FM, Leeuwen-Cornelisse IS et al. Familial adenomatous polyposis and its clinical surveillance. Neth J Med 1993; 42(3-4):105-108.

  62. Bulow S, Bulow C, Nielsen TF, Karlsen L, Moesgaard F. Centralized registration, prophylactic examination, and treatment results in improved prognosis in familial adenomatous polyposis. Results from the Danish Polyposis Register. Scand J Gastroenterol 1995; 30(10):989-993.

  63. Herrera L, Kakati S, Gibas L, Pietrzak E, Sandberg AA. Gardner syndrome in a man with an interstitial deletion of 5q. Am J Med Genet 1986; 25(3):473-476.

  64. Bodmer WF, Bailey CJ,  Bodmer J, Bussey HJ, Ellis A, Gorman P et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 1987; 328(6131):614-616.

  65. Leppert M, Dobbs M, Scambler P, O'Connell P, Nakamura Y, Stauffer D et al. The gene for familial polyposis coli maps to the long arm of chromosome 5. Science 1987; 238(4832):1411-1413.

  66. Powell SM, Petersen GM, Krush AJ, Booker S, Jen J, Giardiello FM et al. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 1993; 329(27):1982-1987.

  67. Bapat B, Noorani H, Cohen Z, Berk T, Mitri A, Gallie B et al. Cost comparison of predictive genetic testing versus conventional clinical screening for familial adenomatous polyposis. Gut 1999; 44(5):698-703.

  68. Moore J, Cowled P. Hereditary non-polyposis colorectal cancer syndrome. Aust N Z J Surg 1999; 69(1 ):6-13.

  69. Mecklin JP. Frequency of hereditary colorectal carcinoma. Gastroenterology 1987; 93(5):1021-1025.

  70. Evans DG, Walsh S, Jeacock J, Robinson C, Hadfield L, Davies DR et al. Incidence of hereditary non-polyposis colorectal cancer in a population-based study of 1137 consecutive cases of colorectal cancer. Br J Surg 1997; 84(9):1281-1285.

  71. Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomaki P et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease [see comments]. N Engl J Med 1998; 338(21):1481-1487.

  72. Ponz DL, Sassatelli R, Benatti P, Roncucci L. Identification of hereditary nonpolyposis colorectal cancer in the general population. The 6-year experience of a population-based registry. Cancer 1993; 71(11):3493-3501.

  73. Aarnio M, Mecklin JP,  Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64(6):430-433.

  74. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.  Gastroenterol  1999;116:1453-1456.

  75. Wijnen J, Khan PM, Vasen H, van der KH, Mulder A, Leeuwen-Cornelisse I et al. Hereditary nonpolyposis colorectal cancer families not complying with the Amsterdam criteria show extremely low frequency of mismatch-repair-gene mutations. Am J Hum Genet 1997; 61(2):329-335.

  76. Temple LK, McLeod RS,  Darlington G, Madlensky L, Bapat B, Wright J et al. Lack of clinically relevant identifiers in heredity nonpolyposis colorectal cancer families with MSH2 and MLH1 gene germline mutations. Submitted for publication 2000.

  77. Burke W, Petersen G, Lynch P, Botkin J, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I.  Hereditary nonpolyposis colon cancer.  Cancer Genetics Studies Consortium.  JAMA 1997; 277(11):915-919.

  78. Vasen HF, Taal BG, Griffioen G, Nagengast FM, Cats A, Menko FH et al. Clinical heterogeneity of familial colorectal cancer and its influence on screening protocols. Gut 1994; 35(9):1262-1266.

  79. Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P et al.  Controlled 15 year trial on screening for colorectal cancer in families with HNPCC.  Gastroenterol  2000;118:829-834.

  80. Lanspa SJ, Jenkins JX, Cavalieri RJ, Smyrk TC, Watson P, Lynch J et al. Surveillance in Lynch syndrome: how aggressive? Am J Gastroenterol 1994; 89(11):1978-1980.

  81. Vasen HF, van Ballegooijen M, Buskens E, Kleibeuker JK, Taal BG, Griffioen G et al. A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 1998; 82(9):1632-1637.

  82. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer [see comments]. N Engl J Med 1994; 331(25):1669-1674.

  83. Winawer SJ, Zauber AG, Gerdes H, O'Brien MJ, Gottlieb LS, Sternberg SS et al. Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Workgroup [see comments]. N Engl J Med 1996; 334(2):82-87.

  84. Ahsan H, Neugut AI, Garbowski GC, Jacobson JS, Forde KA, Treat MR et al. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med 1998; 128(11):900-905.

  85. St.John DJ, McDermott FT, Hopper JL, Debney EA, Johnson WR, Hughes ES. Cancer risk in relatives of patients with common colorectal cancer. Ann Intern Med 1993; 118(10):785-790.

  86. Rozen P, Fireman Z, Figer A, Legum C, Ron E, Lynch HT. Family history of colorectal cancer as a marker of potential malignancy within a screening program. Cancer 1987; 60(2):248-254.

  87. Sackett DL. Bias in analytic research. J Chronic Dis 1979; 32(1-2):51-63.

  88. Pariente A, Milan C, Lafon J, Faivre J. Colonoscopic screening in first-degree relatives of patients with 'sporadic' colorectal cancer: a case-control study. The Association Nationale des Gastroenterologues des Hopitaux and Registre Bourguignon des Cancers Digestifs (INSERM CRI 9505) [see comments]. Gastroenterology 1998; 115(1):7-12.

  89. Guillem JG, Forde KA,  Treat MR, Neugut AI, O'Toole KM, Diamond BE. Colonoscopic screening for neoplasms in asymptomatic first-degree relatives of colon cancer patients. A controlled, prospective study [see comments]. Dis Colon Rectum 1992; 35(6):523-529.

  90. Sauar J, Hausken T, Hoff G, Bjorkheim A, Foerster A, Mowinckel P. Colonoscopic screening examination of relatives of patients with colorectal cancer. I. A comparison with an endoscopically screened normal population. Scand J Gastroenterol 1992; 27(8):661-666.

  91. Pignone M, Campbell MK, Carr C, Phillips C : Systematic review and meta-analysis of the effect of dietary restriction on completion and positively rates for fecal occult  blood testing. Submitted for publication. 

  92. Ontario Expert Panel on Colorectal Cancer.  Draft report of the Ontario Expert Panel on Colorectal Cancer.  1999.

  93. Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112(2):594-642.

  94. Hill M, Faivre J, Giacosa A. Preventative Policies: A Global Perspective. In: GP Young, Prozen BL, editors. Prevention and Early Detection of Colorectal Cancer. London: WB Saunders , 1996.

  95. Recommendations on Population on Screening for Colorectal Cancer in New Zealand.  National Health Committee working Party on Population Screening for Colorectal Cancer.       Aust N Zealand J Med  1999;112:4-6.

  96. Fenlon HM, Nunes DP, Schroy PC, Barish MA, Clarke PD, Ferrucci JT : A comparison of virtual and conventional colonoscopy for the detection of colorectal polyps.  N Engl J Med  1999;341:1496-1503.

  97. Sonnenberg A, Delco F, Inadomi JM : Cost effectiveness of colonoscopy in screening for colorectal cancer.  Ann Intern Med  2000;133:573-584.